PE20191137A1 - Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) - Google Patents
Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1)Info
- Publication number
- PE20191137A1 PE20191137A1 PE2019001297A PE2019001297A PE20191137A1 PE 20191137 A1 PE20191137 A1 PE 20191137A1 PE 2019001297 A PE2019001297 A PE 2019001297A PE 2019001297 A PE2019001297 A PE 2019001297A PE 20191137 A1 PE20191137 A1 PE 20191137A1
- Authority
- PE
- Peru
- Prior art keywords
- cyp11a1
- monooxygenase
- inhibitors
- cytochrome
- pyrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
SE REFIERE COMPUESTOS DERIVADOS DE PIRANO DE FORMULA (I) DONDE R1, R2, R3, R4, R5, R23, R24, L, LOS ANILLOS A Y B SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 2-(ISOINDOLIN-2-ILMETIL)-5-((4-(PIRROLIDIN-1-ILSULFONIL)BENCIL)OXI)-4H-PIRAN-4-ONA; 4-(((6-(ISOINDOLIN-2-ILMETIL)-4-OXO-4H-PIRAN-3-IL)OXI)METIL)-N-METILBENCENOSULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL CITOCROMO P450 MONOOXIGENASA 11A1 (CYP11A1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE PROSTATA, CANCER DE MAMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191137A1 true PE20191137A1 (es) | 2019-09-02 |
Family
ID=61005837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001297A PE20191137A1 (es) | 2016-12-22 | 2017-12-21 | Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10717726B2 (es) |
| EP (2) | EP3558981B1 (es) |
| JP (2) | JP7025432B2 (es) |
| KR (3) | KR102491308B1 (es) |
| CN (2) | CN116162084B (es) |
| AR (1) | AR110412A1 (es) |
| AU (2) | AU2017380282B2 (es) |
| CA (1) | CA3047370A1 (es) |
| CL (1) | CL2019001728A1 (es) |
| CO (1) | CO2019007321A2 (es) |
| CY (1) | CY1124461T1 (es) |
| DK (1) | DK3558981T3 (es) |
| EA (1) | EA039309B1 (es) |
| ES (1) | ES2880151T3 (es) |
| HR (1) | HRP20211255T1 (es) |
| HU (1) | HUE056540T2 (es) |
| IL (2) | IL267484B (es) |
| LT (1) | LT3558981T (es) |
| MA (2) | MA47102B1 (es) |
| MX (1) | MX388538B (es) |
| NZ (1) | NZ755395A (es) |
| PE (1) | PE20191137A1 (es) |
| PH (1) | PH12019550111A1 (es) |
| PL (1) | PL3558981T3 (es) |
| PT (1) | PT3558981T (es) |
| RS (1) | RS62198B1 (es) |
| SI (1) | SI3558981T1 (es) |
| TN (1) | TN2019000189A1 (es) |
| TW (2) | TWI796205B (es) |
| UA (1) | UA124640C2 (es) |
| WO (1) | WO2018115591A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
| KR20230010723A (ko) * | 2020-05-14 | 2023-01-19 | 오리온 코포레이션 | Cyp11a1 억제제 |
| CN116724034A (zh) * | 2020-12-01 | 2023-09-08 | 奥赖恩公司 | 作为用于治疗前列腺癌的cyp11a1抑制剂的2,3-二氢-4h-苯并[b][1,4]噁嗪-4-基(5-(苯基)-吡啶-3-基)甲酮衍生物和类似化合物 |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| KR20230165774A (ko) | 2021-03-01 | 2023-12-05 | 오리온 코포레이션 | 4h-피란-4-온 구조의 cyp11a1 억제제의 고체 형태 |
| BR112023017472A2 (pt) * | 2021-03-01 | 2023-11-07 | Orion Corp | Processo para a preparação de um inibidor de cyp11a1 e intermediários do mesmo |
| BR112023027282A2 (pt) | 2021-06-23 | 2024-03-12 | Orion Corp | Processos para a preparação de compostos inibidores de cyp11a1 e compostos intermediários dos mesmos |
| KR20240068666A (ko) * | 2021-09-28 | 2024-05-17 | 오리온 코포레이션 | 전립선 암의 치료에서 사용하기 위한 cyp11a1 저해제 |
| WO2023073285A1 (en) | 2021-10-28 | 2023-05-04 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor |
| US20250011285A1 (en) | 2021-11-10 | 2025-01-09 | Orion Corporation | Cyp11a1 inhibitors |
| JP2025502308A (ja) | 2022-01-20 | 2025-01-24 | オリオン・コーポレーション | Ｃｙｐ１１ａ１阻害剤の医薬組成物 |
| JP7645296B2 (ja) * | 2022-02-08 | 2025-03-13 | ディーエヌエフ カンパニー リミテッド | ヨウ素含有金属化合物およびこれを含む薄膜蒸着用組成物 |
| CN118307519A (zh) * | 2023-01-06 | 2024-07-09 | 上海闻耐医药科技有限公司 | 一类cyp11a1抑制剂化合物及其制备方法和用途 |
| KR20240126916A (ko) | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
| TW202440557A (zh) * | 2023-03-29 | 2024-10-16 | 大陸商西藏海思科製藥有限公司 | Cyp11a1抑制劑及其用途 |
| AU2024256911A1 (en) * | 2023-04-21 | 2025-11-20 | Xizang Haisco Pharmaceutical Co., Ltd. | Cyp11a1 inhibitors and use thereof |
| AU2024270498A1 (en) * | 2023-05-11 | 2025-11-27 | Foshan Ionova Biotherapeutics Co., Inc. | Novel compounds as cyp11a1 inhibitors and methods of use thereof |
| WO2025017072A1 (en) | 2023-07-19 | 2025-01-23 | Orion Corporation | Stable pharmaceutical compositions of a cyp11a1 inhibitor |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| WO2025051216A1 (zh) * | 2023-09-08 | 2025-03-13 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2025237211A1 (zh) * | 2024-05-11 | 2025-11-20 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的晶型物及其制备方法和应用 |
| WO2025247149A1 (zh) * | 2024-05-27 | 2025-12-04 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| US7344700B2 (en) * | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| EP1471063A1 (en) | 2003-02-28 | 2004-10-27 | Exonhit Therapeutics S.A. | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| AR110412A1 (es) | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es active IP Right Grant
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active Active
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2017-12-21 CN CN202211597796.4A patent/CN116162084B/zh active Active
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 KR KR1020237002074A patent/KR102826021B1/ko active Active
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en not_active Withdrawn
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 MX MX2019007373A patent/MX388538B/es unknown
- 2017-12-21 NZ NZ755395A patent/NZ755395A/en unknown
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en not_active Ceased
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 KR KR1020257020993A patent/KR20250097993A/ko active Pending
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US12030871B2/en active Active
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
-
2024
- 2024-05-24 US US18/674,603 patent/US20240308989A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191137A1 (es) | Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1) | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| PE20210642A1 (es) | Inhibidores de pd-1/pd-l1 | |
| CO2019011543A2 (es) | Inhibidores de pd-1/pd-l1 | |
| CL2017002929A1 (es) | Compuestos fungicidas | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| PE20210640A1 (es) | Inhibidores pd-1/pd-l1 | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| UY36462A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| PE20171338A1 (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
| CL2017000521A1 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| UY36999A (es) | Derivados de aryl oxadiazol fungicidas | |
| PE20161073A1 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CL2019000512A1 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20170662A1 (es) | Compuestos de aminopiridiloxipirazol | |
| PE20161438A1 (es) | Inhibidores de desmetilasa 1 especifica a lisina | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| PE20161476A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| PE20191142A1 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| ECSP17010238A (es) | Compuestos novedosos de pirimidina sustituidos |